Medication | Starting dose | Usual effective dose range | Common side effects | Rare but serious side effects |
Sodium oxybate¶ | Doses are administered twice nightly, at bedtime and 2.5 to 4 hours later Recommended starting dose by weight:
| 2 to 9 grams in 2 divided doses at night Maximum recommended total night dose by weight:
| Morning sedation, nausea, weight loss, dizziness, enuresis, sleepwalking, tremor, worsening of OSA | Confusion, severe sedation, central sleep apnea, coma, diversion or misuse¶ |
Mixed-salt oxybate (calcium, magnesium, potassium, and sodium oxybates)¶ | Same as for sodium oxybate | Same as for sodium oxybate | Same as for sodium oxybate | Same as for sodium oxybate |
PitolisantΔ | By weight:
| By weight:
| Headache, insomnia, nausea, anxiety | Severe rash, QT prolongation |
Tricyclic antidepressants | ||||
Clomipramine◊ | 25 mg at bedtime | 25 to 100 mg/day at bedtime | Dry mouth, constipation, sweating, blurry vision, somnolence, weight gain, orthostatic hypotension | Cardiotoxicity, seizures, suicidal ideation, bone marrow suppression, serotonin syndrome |
Imipramine | 25 mg once daily | 25 to 75 mg/day in 1 to 2 divided doses | ||
Protriptyline◊ | 5 mg once daily | 5 to 10 mg/day in 1 to 2 divided doses | ||
Selective serotonin reuptake inhibitors | ||||
Fluoxetine | 5 to 10 mg once daily | 10 to 30 mg once daily | Nausea, insomnia, tremor | Suicidal ideation, prolongation of QT interval, serotonin syndrome |
Sertraline | 12.5 to 25 mg once daily | 25 to 200 mg once daily | ||
Citalopram | 10 mg once daily | 10 to 40 mg once daily | ||
Serotonin norepinephrine reuptake inhibitors | ||||
Venlafaxine | 25 mg once daily | 37.5 to 75 mg once daily | Nausea, weight loss, dizziness, headache, constipation, insomnia, somnolence, tremor | Suicidal ideation, prolongation of QT interval, serotonin syndrome |
OSA: obstructive sleep apnea.
* Doses listed in table are appropriate for children ≥6 years and adolescents (except as noted).
¶ Dosing shown for children ≥7 years and adolescents; guidance for such children weighing <20 kg provided in Lexicomp drug information. In the United States, prescribers must register with the Risk Evaluation and Mitigation Strategies (REMS) program and follow specific safety and monitoring recommendations. Combined use with alcohol, sedatives, or hypnotics is specifically contraindicated in United States licensing information.
Δ Authorized by the European Medicines Agency for use in children ≥6 years and adolescents; in the United States and Canada, approval is limited to adults ≥18 years. Dosing is expressed as pitolisant base and corresponds with tablet strengths available in the United States. International products may express dosing differently (eg, as pitolisant hydrochloride or approximate pitolisant base amount) depending on country. Refer to local product information.
◊ Dosing shown for children ≥10 years and adolescents.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟